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Abstract Death of macrophages and smooth muscle cells
(SMC) can lead to progression of atherosclerosis. Mildly oxi-
dised low-density lipoprotein (mildly-oxLDL) induced more
overall death and apoptosis than moderately oxidised LDL, in
human monocyte-macrophages (HMM). Mildly-oxLDL also in-
duced more overall death in human SMC than did moderately-
oxLDL. Mildly-oxLDL contained more hydroperoxides, but
less oxysterol, malondialdehyde and negative charge than mod-
erately-oxLDL. Speci¢c inhibition of lipoprotein-associated
phospholipase A2 (by SB222657) diminished death induction in
HMM by both oxLDL types. Peroxisome proliferator-activated
receptor Q (PPARQ) antagonist (GW9662) and agonist (ciglita-
zone) experiments suggested that non-hydrolysed, oxidised phos-
pholipids in oxLDL activate PPARQ as a cellular defence mech-
anism. These results may be relevant to LDL oxidation within
atherosclerotic plaques and may suggest strategies for combat-
ing atherosclerosis progression.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Death of macrophages and smooth muscle cells (SMC) oc-
curs in human advanced atherosclerotic lesions (plaques), by
apoptosis and necrosis [1^3]. Macrophage foam cells that die
and are not phagocytosed can spill lipid into the extracellular
environment and so contribute to the lipid core of the plaque
[3,4], whilst death of SMC erodes the ¢brous cap [2]. Such
changes destabilise plaques, increasing the risk of rupture and
consequent thrombosis [5^7].
Evidence implicating oxidation of low-density lipoprotein
(LDL) in atherosclerosis progression includes that oxidised
LDL (oxLDL) and lipid peroxidation products occur in ath-
erosclerotic lesions [8^10], and that oxLDL is toxic and apo-
ptosis-inducing for macrophages and SMC in vitro [11^15].
OxLDL contains a complex, variable, incompletely charac-
terised mixture of toxic oxidation products. Lipid hydroper-
oxides appear relatively early on in the oxidation and alde-
hydes arise from their subsequent breakdown [16]. Aldehydes
modify the LDL protein (apoB-100), increasing its negative
charge [16]. Cholesterol oxidation products (also termed oxy-
sterols) appear consequentially to the peroxidation of polyun-
saturated fatty acids (PUFA) within LDL [17,18]. The LDL-
borne enzyme lipoprotein-associated phospholipase A2 (Lp-
PLA2), also termed platelet-activating factor acetylhydrolase,
hydrolyses oxidised phosphatidylcholine (oxPC), but not non-
oxidised phosphatidylcholine (PC), producing lysophosphati-
dylcholine (lyso-PC) and oxidised, non-esteri¢ed fatty acids
(oxNEFA)[19,20].
Lipid oxidation products can activate cell transcription fac-
tors known as peroxisome proliferator-activated receptors
(PPAR), especially PPARQ, which may induce apoptosis. Var-
ious synthetic PPARQ activators induced apoptosis in vitro, in
macrophages [21] and in cancer cell lines [22,23]. A natural
PPARQ activator, 15-deoxy-v12,14-prostaglandin J2 (15d-
PGJ2), a cyclo-oxygenase metabolite of arachidonic acid, in-
duced apoptosis in vitro, in macrophages and endothelial cells
[21,24]. OxLDL and certain LDL oxidation products, 9- and
13-hydroxyoctadecadienoic acids, activated PPARQ in CV-1
cells [25]. In human atherosclerotic lesions, PPARQ occurs in
macrophages in a pattern highly correlated with oxidation-
speci¢c epitopes [26^28].
A moderately oxidised form of LDL decreased SMC via-
bility and induced SMC apoptosis in vitro, whereas a more
strongly oxidised form of LDL did not, and neither did a very
mildly oxidised form of LDL or native LDL (natLDL)[15]. In
macrophages, moderately oxidised LDL induced death, in-
cluding apoptosis, which was diminished by inhibiting Lp-
PLA2 within natLDL prior to oxidation [20]. The present
study’s purpose was to investigate the e¡ect of degree of
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LDL oxidation, focusing on mild and moderate degrees, on
macrophage death (overall death, as well as apoptosis), and to
explore the roles of Lp-PLA2 and PPARQ therein. SMC were
compared in selected cases.
2. Materials and methods
Ciglitazone and M199 medium were from Sigma. SB222657 and
GW9662 were gifts of Glaxo SmithKline. Other materials were as
described previously [20]. Dimethyl sulphoxide (¢nal concentration
9 0.5% v/v) was the solvent vehicle for ciglitazone, SB222657 and
GW9662.
Isolation (from bu¡y coat) and culture conditions for human
monocyte-macrophages (HMM) were as described previously [20].
HMM were cultured for 1 day before starting experiments, unless
stated otherwise. Mature HMM were produced by culturing mono-
cytes for 4^5 days before starting experiments. All HMM cultures and
experiments were in Gibco Macrophage-SFM (serum-free medium), in
24-well plates. SMC derived from human aortic explants were cul-
tured in M199 medium (Sigma) plus 20% foetal calf serum (FCS) in
T75 (75-cm2) tissue culture £asks (Falcon, Becton Dickinson). Me-
dium was renewed every 2^3 days. Cultures were passaged when near-
ing con£uence, and were not used above passage 11. For toxicity
experiments, SMC were plated into 24-well plates in M199 (without
phenol red) plus 2% FCS and were used at c. 80% con£uence.
Isolation of natLDL and oxidation at 1 mg LDL protein/ml by
Cu2þ ions (10 WM) in phosphate-bu¡ered saline (PBS; pH 7.4) for
15 h at 37‡C, producing moderately-oxLDL (ox(3)LDL) were as de-
scribed previously [20]. We adapted Fe2þ-mediated LDL oxidation
conditions from the literature [16,29,30], as follows. Fe2þ ions (iron-
(II) sulphate, 10 WM) were used to oxidise LDL (1 mg LDL protein/
ml) for 15 h at 37‡C, either in saline (sodium chloride 0.9% w/v in
high-purity Milli-Q deionised water) producing mildly-oxLDL
(ox(2)LDL) or at pH 5.5 in PBS producing very mildly-oxLDL
(ox(1)LDL). Treatment of natLDL with SB222657 (2 WM) or Pefabloc
(PFB; 500 WM) prior to oxidation was as described previously [20].
After 15 h oxidation, oxLDLs were Chelex-treated and diluted to
250 Wg LDL protein/ml with culture medium for incubation with cells.
Triplicate or duplicate culture wells of cells were used for each oxLDL
(or control) treatment for the nucleosome enzyme-linked immuno-
sorbent assay (ELISA) and triplicate culture wells for the lactate de-
hydrogenase (LDH) release assay (see below). Incubations of oxLDLs
with cells were for 48 h unless stated otherwise. Negative controls
were cells incubated in these media with no additions (NA), or with
natLDL. Gliotoxin (3 WM), an established apoptosis-inducing agent
for HMM, was used for a positive control.
Total hydroperoxides were measured by the ferrous oxidation of
xylenol orange (FOX) assay, version ‘FOX2’ [31], and in selected
cases additionally by an iodometric method [32]. Other assays were
as described previously [20].
Data are reported as meanRS.E.M.; n is the number of individual
specimens or culture wells. Statistical analysis was by ANOVA and
Student’s t-test (unpaired), using StatView 5.0.1 software. The level of
signi¢cance was P6 0.05. Experiments were repeated several times
and representative data are presented.
3. Results and discussion
Ox(3)LDL, ox(2)LDL and ox(1)LDL were compared for
cell death-inducing e¡ects and for chemical composition.
Ox(2)LDL induced signi¢cantly more overall death of
HMM than ox(3)LDL, measured by the LDH release assay
(Fig. 1). Likewise, for SMC, LDH release after 48 h was
signi¢cantly higher (P=0.0009) for ox(2)LDL (73.2 R 0.6%,
n=3) than for ox(3)LDL (44.2 R 3.2%, n=3). SMC LDH re-
lease was 12.2R 1.2% (n=3) for NA and 13.4R 1.7% (n=3)
for natLDL. Ox(2)LDL induced signi¢cantly more HMM ap-
optosis (measured by nucleosome ELISA) than did ox(3)LDL
(Fig. 2). Ox(1)LDL was non-toxic to HMM, measured by
LDH release (Fig. 1), although it induced a low (yet statisti-
cally above-background) degree of HMM apoptosis (Fig. 2),
less than ox(3)LDL.
Time-course measurements (0^24 h; Fig. 3) by the FOX
assay and relative electrophoretic mobility (REM) on agarose
gels demonstrated that 15 h oxidation appeared optimal for
di¡erentiating composition between the three types of oxLDL,
and so was adopted to prepare oxLDLs for cell death induc-
tion studies, reported above. During moderate LDL oxida-
Fig. 1. Cytotoxicity of oxLDLs, measured by the LDH release assay
in HMM, after 48 h exposure. Control cells were cultured without
LDL or oxLDLs, i.e. NA. The su⁄xes -sb or -pfb indicate that the
oxLDL was prepared with pretreatment (prior to oxidation) of
natLDL with SB222657 or with PFB. Each histogram bar represents
meanRS.E.M., n=9^15. ANOVA P6 0.0001. **P6 0.01,
*P=0.037, signi¢cantly di¡erent from the corresponding oxLDL
prepared without SB222657 or PFB pretreatment. #P=0.0323,
ox(2)LDL signi¢cantly di¡erent from ox(3)LDL. OxLDLs were sig-
ni¢cantly di¡erent from NA (P6 0.05), except for ox(1)LDL and
ox(1)LDL-sb.
Fig. 2. Apoptosis, measured by nucleosome ELISA, in HMM ex-
posed to oxLDLs for 48 h. Each histogram bar represents meanR
S.E.M., n=5^9. ANOVA P6 0.0001. **P=0.0002, *P=0.027, sig-
ni¢cantly di¡erent from the corresponding oxLDL prepared without
SB222657 pretreatment. #P=0.0232, ox(2)LDL signi¢cantly di¡erent
from ox(3)LDL. Gliotoxin (3 WM for 4 h), a positive control, gave
absorbance 0.389R 0.019 (n=6). OxLDLs were signi¢cantly di¡erent
from NA (P6 0.05), except for ox(2)LDL-sb, ox(1)LDL-sb and
ox(1)LDL-pfb.
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tion, hydroperoxides peak early on, and then decline rapidly.
For mild LDL oxidation, hydroperoxides peak later and re-
main high, as decline is slow. After 15 h oxidation, ox(2)LDL
consistently contained higher levels of hydroperoxides (FOX
assay), lower levels of oxysterols measured by gas chromatog-
raphy (GC), lower levels of malondialdehyde (MDA) equiv-
alents measured by the thiobarbituric acid-reactive substances
(TBARS) assay and lower REM (i.e. less negative charge),
than did ox(3)LDL (Fig. 4). Hydroperoxide levels in
ox(1)LDL were only slightly above natLDL, whilst REM,
TBARS and 7L-hydroxycholesterol in ox(1)LDL were similar
Fig. 3. Time course of LDL oxidation. a: REM, measured on aga-
rose gels. b: Levels of hydroperoxides, assayed in triplicate (data
points are means) by the FOX method, for ox(3)LDL, ox(2)LDL
and ox(1)LDL.
C
Fig. 4. Degree of oxidation of oxLDLs used for cell death studies.
Oxidation was for 15 h. Levels of (a) hydroperoxides, measured by
the FOX assay, (b) MDA equivalents, measured by the TBARS as-
say, (c) 7L-hydroxycholesterol, measured by GC and (d) REM, mea-
sured on agarose gels. Each histogram bar represents meanR
S.E.M., n= (a) 9^18, (b) 7^17, (c) 5^6, except for ox(1)LDL, 2,
ox(1)LDL-sb, 2, and ox(1)LDL-pfb, 2, (d) 9^19. ANOVA
P6 0.0001 for each of a^d. #Ox(2)LDL signi¢cantly di¡erent from
ox(3)LDL, (a) P=0.0209, (b) P=0.026, (c) P=0.0012, (d)
P6 0.0001. Corresponding oxLDLs prepared with or without
SB222657 or PFB pre-treatment were not signi¢cantly di¡erent from
each other. OxLDLs were signi¢cantly di¡erent from natLDL
(P6 0.05), except for (a) ox(1)LDL-sb, (b^d) ox(1)LDL, ox(1)LDL-
sb and ox(1)LDL-pfb.
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to natLDL (Fig. 4). Hydroperoxide results by the iodometric
method (data not shown) were similar to the FOX assay.
The nucleosome ELISA measures cytoplasmic histone-asso-
ciated DNA fragments (mono- and oligo-nucleosomes), apo-
ptosis markers arising from internucleosomal cleavage as a
result of activation of endogenous endonucleases and pro-
teases. We also used acridine orange (AO) staining of
HMM (¢xed in ethanol^PBS 70:30 v/v) to measure apoptosis
by £uorescence microscopy as percentage of HMM with mor-
phologically condensed nuclear chromatin, another character-
istic of apoptosis [33]. In principle, nuclear condensation can
occur before DNA fragmentation. Such cell counts are, how-
ever, less quantitatively discriminating than the nucleosome
ELISA. Assessed by AO staining, ox(2)LDL and ox(3)LDL
appeared both very potent, respectively giving apoptotic cells
as 88% and 87% of total cells, whilst natLDL and NA gave
7% and 4% respectively, all after 48 h incubation, and glio-
toxin (3 WM; positive control) gave 88% apoptosis after 24 h.
Ox(1)LDL was not assessed using AO.
Our results suggest that hydroperoxides, which are early-
stage oxidation products, are more potent toxins in oxLDL
than are the more advanced oxidation products such as alde-
hydes and oxysterols. Plotting hydroperoxide levels (FOX as-
say) in natLDL, ox(1)LDL, ox(2)LDL and ox(3)LDL v. %
LDH release measured in HMM (1 day in culture before
starting experiments), after 48 h exposure to these oxLDLs
or natLDL, revealed a highly signi¢cant positive correlation
(least-squares linear regression R2 = 0.586, P6 0.0001, n=51).
Weaker (though still signi¢cant) positive correlations with %
LDH release were seen for 7L-hydroxycholesterol, MDA
equivalents and REM. Hydroperoxide-rich ox(2)LDL might
constitute a ‘loaded weapon’ that can decompose at the cell
surface membrane and/or within the cell to give high local
concentrations of aldehydes and free radicals. The results
for ox(1)LDL suggest that a low, though above-background,
level of hydroperoxides (and possibly other uncharacterised
entities produced in the earliest stages of LDL oxidation)
could trigger a low degree of apoptosis but not yet lead to
loss of integrity of the cell surface membrane within the 48 h
duration of the experiment. In contrast, for ox(2)LDL and
ox(3)LDL, apoptosis and loss of cell surface membrane integ-
rity (LDH release) go hand-in-hand by 48 h.
The hydroperoxides detected are probably derived from
PUFAs (esteri¢ed and non-esteri¢ed) rather than from choles-
terol (esteri¢ed and non-esteri¢ed), as our oxysterol assay
protocol, which included a sodium borohydride (NaBH4) re-
duction step in the sample processing, would encompass cho-
lesterol hydroperoxides by converting them to the correspond-
ing hydroxides. Hydroperoxides are thermally unstable, so
would decompose on GC. NaBH4 also converts any 7-keto-
cholesterol present to 7L-hydroxycholesterol (c. 85%) and to
7K-hydroxycholesterol (c. 15%) [34]. Because it elutes very
close to cholesterol, we do not normally quantify 7K-hydroxy-
cholesterol by this analytical protocol [35]. The 7L-hydroxy-
cholesterol levels in Fig. 4 are thus e¡ectively a summation of
the oxysterols 7-ketocholesterol, 7L-hydroperoxycholesterol
and 7L-hydroxycholesterol present in the original samples.
All the above oxysterols are cytotoxic [36^38]. Part of the
TBARS detected might arise from decomposition of fatty
acid hydroperoxides originally present in the samples, forming
MDA during the necessary heating step of the assay [39],
thereby possibly underestimating the di¡erential between
ox(2)LDL and ox(3)LDL for MDA levels. Hydroperoxides
are ‘reaction intermediates’ chemically, rising then declining
as the oxidation progresses [16], whereas 7L-hydroxycholester-
ol and REM are cumulative markers of oxidation that rise
and do not decline even for strong, prolonged oxidation [18].
Toxicity was not due to residual free Fe2þ or Cu2þ ions
remaining in solution after the Chelex treatment of the
oxLDLs, because controls consisting of solutions of Fe2þ or
Cu2þ that we put through the whole of the preparation pro-
cedure, but omitting the LDL, were non-toxic to HMM.
However, oxLDL-associated iron or copper ions, if not re-
moved by Chelex, might play a role in toxicity, possibly in
conjunction with lipid hydroperoxides in oxLDL. Human ad-
vanced atherosclerotic lesions contain ‘catalytic’ iron and cop-
per ions [40].
Lp-PLA2 is a phospholipase that hydrolyses oxPC possess-
ing an oxidised PUFA chain ester-linked in the sn-2 position,
but does not hydrolyse non-oxidised PC. Lp-PLA2 is a serine
esterase, and is LDL-borne. Also, mature macrophages and to
a lesser degree freshly isolated monocytes secrete Lp-PLA2
identical to LDL-borne Lp-PLA2 [41^43]. Pre-treatment of
natLDL with SB222657, a speci¢c Lp-PLA2 inhibitor [19],
diminished the toxicity and apoptosis induction that ensued
when the LDL was mildly or moderately oxidised and then
added to HMM (Figs. 1, 2 and 5). PFB, a broad-spectrum
serine esterase/protease inhibitor, had a similar e¡ect to
SB222657 on toxicity but did not inhibit the corresponding
apoptosis induction (Figs. 1 and 2). PFB might inhibit anti-
apoptotic serine esterases/proteases, presumably within the
cell. SB222657 and PFB did not act as antioxidants, either
here (Fig. 4) or in earlier studies [19,20], and have no known
chelating ability, consistent with their lack of e¡ect on LDL
oxidation per se (as opposed to hydrolysis).
Our results agree with evidence that Lp-PLA2 can hydro-
lyse oxPC, whether possessing full-length PUFA-hydroperox-
ide chains or oxidatively fragmented PUFA chains, liberating
lyso-PC and oxNEFA [19]. Lyso-PC was more toxic than an
oxPC possessing an oxidatively fragmented PUFA chain, for
HMM [20]. PC is the main phospholipid class in LDL. How-
ever, Lp-PLA2 has rather permissive substrate requirements
[44,45], so it might also hydrolyse oxidised forms of the less
abundant LDL phospholipid classes, and maybe also hydro-
lyse oxidised tri- and di-acylglycerols.
The role of PPAR in oxLDL-induced cell death was ex-
plored using the PPARQ-preferential antagonist GW9662,
which also inhibits PPARK and PPARN less potently, binding
irreversibly to PPAR [46]. Cells were pretreated for 20 h with
2 WM GW9662, which was replenished at 2 WM when the
oxLDLs were added. GW9662 (2 WM) almost completely in-
hibits PPARQ activation [46,47]. GW9662 (2 WM) was not
toxic to HMM or SMC, and it did not signi¢cantly a¡ect
the toxicity of ox(2)LDL or ox(3)oxLDL, for HMM (Fig. 5)
or for SMC (data not shown; Ps 0.05). GW9662 (2 WM)
treatment of HMM tended to counteract the lowering of
the oxLDL toxicity resulting from Lp-PLA2 inhibition with
SB222657, for HMM that had been cultured either for 4 days
(Fig. 5) or for 1 day (data not shown) before starting experi-
ments. Possibly, PPARQ activation by intact (i.e. non-hydro-
lysed) oxPC triggers a cellular defence mechanism. Oxidised
alkyl PC (the O-alkyl linkage in the sn-1 position, and the
oxidised chain ester-linked in the sn-2 position), a sub-class
of oxPC in oxLDL, can speci¢cally bind to and activate PPARQ
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[48]. The binding appeared a characteristic of the intact (non-
hydrolysed) form since oxNEFAs were ine⁄cient competitors
[48]. OxPC can activate PPARK [49], but this requires phos-
pholipase A2 activity [50], suggesting that the oxNEFA there-
by liberated were the actual PPARK ligands. PPARQ thus
appears more likely to be important than PPARK in the pu-
tative defence mechanism triggered by intact oxPC in our
study.
The PPARQ agonist ciglitazone at 3 WM, its EC50 [51], was
innocuous to HMM. The addition of ciglitazone (3 WM) to
mature HMM with ox(3)LDL and ox(2)LDL prepared with
inhibition of Lp-PLA2, by pre-treatment of natLDL with
SB222657, signi¢cantly diminished toxicity, by 27%
(P=0.0374) and 24% (P=0.0032) respectively after 24 h, con-
sistent with a protective role for PPARQ activation by oxPC.
When the SB222657 pre-treatment was omitted, ciglitazone
did not diminish toxicity of the oxLDLs. Ciglitazone and
rosiglitazone had biphasic e¡ects on T-lymphocyte death
[52]. Another PPARQ activator, 15d-PGJ2, was toxic to
HMM [53]. The highly unsaturated arachidonic and docosa-
hexaenoic acids, incubated with HMM under conditions al-
lowing peroxidation, induced both apoptosis and PPARQ ac-
tivation, whereas the less highly unsaturated linoleic and oleic
acids, which were less readily peroxidisable, were innocuous
and did not activate PPARQ [53].
PPARQ activation might thus be a cellular death mechanism
or a defence, depending on conditions. Caveats are that in-
hibitors and activators might have additional non-speci¢c ef-
fects, and that co-demonstration of PPARQ activation and
apoptosis does not prove causation. The putative dual func-
tion of PPARQ ^ defence or death ^ would be broadly akin to
other cellular damage responses, e.g. involving p53 and mis-
match repair, where the cell is either repaired or deleted de-
pending on the degree of damage. PPARQ appears to act
defensively under the present study’s conditions.
Our induction of cell death by very mildly-, mildly- and
moderately-oxLDLs indicates that the presence of strongly
oxidised LDL is not necessary to kill cells, a ¢nding relevant
to atherosclerotic lesions where the overall degree of oxidation
appears less than that of strongly oxidised LDL. Very mildly-
oxLDL induced HMM apoptosis above background, whilst
mildly- and moderately-oxLDLs produced both apoptosis and
overt toxicity. In human advanced atherosclerotic lesions,
macrophage foam cells die by apoptosis and necrosis [3]. Clas-
sical apoptosis and necrosis represent the ends of a continuum
of death modes, with varying contributions of the cellular
machinery, and both apoptosis and necrosis can involve con-
trolled cellular events [54,55].
Macrophage death in lesions may be anti-in£ammatory and
anti-atherogenic if the dying or dead macrophages are e⁄-
ciently scavenged by viable neighbouring macrophages. If
not scavenged, dead macrophages contribute to the lesion’s
acellular lipid core, exacerbating the lesion. Inhibition of Lp-
PLA2 might be ameliorative, as the fewer ensuing dead cells
would be more easily scavenged by the remaining viable mac-
rophages. Since oxPC are epitopes, on oxLDL and on apo-
ptotic cells, recognised by CD36 (scavenger receptor type B)
[56^58], preservation of oxPC by inhibiting their hydrolysis,
by means of inhibiting Lp-PLA2, might improve the e⁄ciency
of scavenging of oxLDL and of apoptotic macrophages.
Whilst theoretically this might increase foam cell formation,
this might be counterbalanced if the oxPC also activate PPARQ,
since activation of PPARQ in macrophages upregulates both
CD36 [59] and the ABCA1 cholesterol e¥ux pathway, and the
latter counteracts the e¡ect of the former [60].
In conclusion, we have shown that mildly-oxLDL, rich in
lipid hydroperoxides, is a potent death inducer for macro-
phages and SMC. Moderately-oxLDL was a less potent,
though clearly signi¢cant, inducer of death in these cell types.
Induction of macrophage death appears partly as a conse-
quence of the hydrolytic action of Lp-PLA2 on oxPC. Ele-
vated plasma levels of Lp-PLA2 were a strong independent
predictor of coronary artery disease in men [61]. Non-hydro-
lysed, oxidised phospholipids in oxLDL may activate PPARQ
in macrophages, as a cellular defensive response. These results
may be relevant to the progression of atherosclerotic lesions
to an unstable, rupture-prone state with thinned ¢brous caps
and enlarged lipid cores, and may suggest dietary and phar-
macological strategies for combating the disease.
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